Dr. Bendell on Remaining Questions With Regorafenib in HCC

Johanna C. Bendell, MD
Published: Friday, Apr 21, 2017



Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

The biggest thing with regorafenib, Bendell says, is how to dose it safely and how to limit the associated toxicities that are observed. The current starting dose is 160 mg daily, but if physicians administer that dose they should educate patients about the toxicities. Patients should also report any related adverse events immediately so physicians can hold treatment before it becomes intolerable.

Some practitioners, though, are starting at lower doses, such as 120 mg or even 80 mg, she says.
SELECTED
LANGUAGE


Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses the remaining questions researchers have with regorafenib (Stivarga) for patients with hepatocellular carcinoma (HCC).

The biggest thing with regorafenib, Bendell says, is how to dose it safely and how to limit the associated toxicities that are observed. The current starting dose is 160 mg daily, but if physicians administer that dose they should educate patients about the toxicities. Patients should also report any related adverse events immediately so physicians can hold treatment before it becomes intolerable.

Some practitioners, though, are starting at lower doses, such as 120 mg or even 80 mg, she says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x